In this DoctoLIVE on Multiple Myeloma, we discussed on exclusive data from our MMsyndiTrack™ study, accompanied by Dr. Philippe RODON, who has participated in our studies for more than 10 years.
We talk about the consequences of clinical developments in the day to day practice, the influence of new drugs on treatment, or also about the future for CAR-T therapy.
Dr. Philippe Rodon is a French Hemato-oncologist, practicing haematology at Périgueux hospital, France.
He is mainly involved in the management of hematological malignancies (acute and chronic ones), especially on Multiple Myeloma. He is member of the french group AFM Board. He is engaged in therapeutic innovation in multiple myeloma and participated in a lot of clinical trials.
Monoclonal antibody medication: chances and place for Isatuximab compared to Darzalex
CAR-T cell and bispecific antibodies: what is the best alternative?
Fill out the form to access the entire recording!
DoctoLIVE: A new opportunity to get answers to your questions directly from actual practitioners, all organized by APLUSA
Why DoctoLIVE? 15 minutes of an HCP’s time booked by APLUSA to answer your practical questions, live.
DoctoLIVE is your window to real-world challenges in real-life healthcare practice, from an actual healthcare practioner's perspective.
DoctoLIVE offers you a 15-minute open-mic discussion featuring a different HCP every session, answering your questions related to real-life treatment experiences. These discussions will be held in English.
We will cover how to implement new therapeutics in actual practice, uncover pain points and discuss areas for improvement.
